

Attorney Docket No.: 03394/100H557-US1

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. _____ in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

EL 996119105 - 45

on

6/29/04
Date

B.W. Lee

Signature

B.W. LEE

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Information Disclosure Statement;
PTO SB/08 Form;
15 References (1US, 1PCT, 13 Articles)



07-01-04

✓

JPW 1646 #

Docket No.: 03394/100H557-US1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Ehud Goldin

Application No.: 09/851,494

Confirmation No.:

Filed: May 8, 2001

Art Unit: 1646

For: A GENE ENCODING A NEW TRP
CHANNEL IS MUTATED IN
MUCOLIPIDOSIS IV

Examiner: J. Ulm

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In order to comply with the duty to disclose information under 37 C.F.R. § 1.56, Applicants submit herewith an Information Disclosure Statement (IDS) in accordance with 37 C.F.R. § 1.97 and § 1.98. In particular, Applicants submit herewith Form PTO/SB/08A (Substitute for Form 1449A/PTO) listing references 1-15 for consideration by the Examiner. A copy of each reference listed on the accompanying Form PTO/SB/08A is also submitted herewith.

This IDS is submitted in accordance with 37 C.F.R. §§ 1.97(b)(3) and after the mailing of our response to the first Office Action on the merits. However, should the U.S. Patent and Trademark Office determine that any fee is required or that any refund is due, the Commissioner is hereby authorized and requested to charge the required fee and/or credit any refund to our Deposit Account No. 04-0100.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited on the accompanying Form PTO/SB/08A be given thorough consideration and that

{W:\03394\100H557US1\00206966.DOC [REDACTED] }

07/02/2004 JBALIWAH 00000113 040100 09851494
01 FC:1806 180.00 DA

it be cited of record in the prosecution history of the present application by initialing that form in the space I hereby certify that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

A copy of each document on the PTO/SB/08 is attached. A concise explanation of relevance of the items listed on form PTO/SB/08 is given.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

A check in the amount of \$180 to cover the fee for submitting an Information Disclosure Statement pursuant to 37 CFR 1.97(c) is enclosed. The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: June 23, 2003

Respectfully submitted,

By Paul F. Fehlner
Paul F. Fehlner, Ph.D.
Registration No.: 35,135
DARBY & DARBY P.C.
P.O. Box 5257
New York, New York 10150-5257
(212) 527-7700
(212) 753-6237 (Fax)
Attorneys/Agents For Applicant

The PTO did not receive the following
listed item(s) \$180.00 check



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	09/851,494
				Filing Date	May 8, 2001
				First Named Inventor	Ehud Goldin et al.
				Art Unit	1646
				Examiner Name	John D. Ulm
Sheet	1	of	2	Attorney Docket Number	03394/100H557-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-6,300,096	10-09-2001	Stahl et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	2	WO-WO 01/77331 A1	10-18-2001	Curtis et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	3	"From Worm To Man: Three Subfamilies of TRP Channels", CHRISTIAN HARTENECK ET AL., Trends Neurosci., Vol. 23, No. 4, 2000, Elsevier Science Ltd., 2000	
	4	"Compromised Cytoarchitecture and Polarized Trafficking in Autosomal Dominant Polycystic Kidney Disease Cells", AUDRA J. CHARRON ET AL., The Journal of Cell Biology, Vol. 149, No. 1, 4/3/00, The Rockefeller University Press	
	5	"Cellular and Subcellular Distribution of Polycystin-2, the Protein Product of the PKD2 Gene", LUKAS FOGGENSTEINER ET AL., Journal of the American Society of Nephrology, 2000	
	6	"Ion Channels and Synaptic Organization: Analysis of the Drosophila Genome", J. TROY LITTLETON ET AL., Neuron, Vol. 26, 35-43, April 2000, Cell Press 2000	
	7	"Mucopolipidosis IV Consists of One Complementation Group", EHUD GOLDIN ET AL., Proc. Natl. Acad. Sci., USA, Vol. 96, pp. 8562-8566, July 1999, Genetics	
	8	"Mapping of the Mucopolipidosis Type IV Gene to Chromosome 19p and Definition of Founder Haplotypes.", SUSAN A. SLAUGENHAUPT ET AL., The American Society of Human Genetics, 1999	
	9	"Mucopolipidosis Type IV Characteristic MRI Findings", DR. K.P. FREI ET AL., American Academy of Neurology, 1998	
	10	"Abnormal Transport Along the Lysosomal Pathway in Mucopolipidosis, Type IV Disease", CHII-SHIARNG CHEN ET AL., Proc. Natl. Acad. Sci., USA, Vol. 95, pp 6373-6378, May 1998, Medical Sciences.	
	11	"Constitutive Achlorhydria in Mucopolipidosis Type IV", RAPHAEL SCHIFFMANN ET AL., Proc. Natl. Acad. Sci., USA, Vol. 95, pp 1207-1212, February 1998, Medical Sciences	
	12	"Recommendations for a Nomenclature System for Human Gen Mutations", DR. STYLIANOS E. ANTONARAKIS ET AL., Human Mutation 11:1-3 (1998), Wiley-Liss, Inc. 1998	
	13	"Cultured Skin Fibroblasts Derived From Patients With Mucopolipidosis 4 Are Auto-Fluorescent",	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/851,494
				Filing Date	May 8, 2001
				First Named Inventor	Ehud Goldin et al.
				Art Unit	1646
				Examiner Name	John D. Ulm
Sheet	2	of	2	Attorney Docket Number	03394/100H557-US1

		EHUD GOLDIN ET AL., Pediatric Research, Vol. 37, No. 6, 1995, International Pediatric Research Foundation, Inc. 1995	
	14	"The Effect of Lysosomal Storage Diseases on Secretory Cells: An Ultrastructural Study of Pancreas as an Example", I. HAMMEL ET AL.; J. Submicrosc. Cytol., Pathology, 27 (2), 143-160, 1995	
	15	"G' to 'A' Mutation at Position -1 of a 5' Splice Site in a Late Infantile Form of Tay-Sachs Disease", SAID AKLI ET AL., The Journal of Biological Chemistry, Vol. 265, No. 13, Issue of May 5, pp. 7324-7330, 1990, The American Society For Biochemistry and Molecular Biology, Inc. 1990	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--